Correlation Between Syndax Pharmaceuticals and Eterna Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Eterna Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Eterna Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Syndax Pharmaceuticals and Eterna Therapeutics, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Eterna Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Eterna Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Eterna Therapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and Eterna Therapeutics

0.7
  Correlation Coefficient

Poor diversification

The 3 months correlation between Syndax and Eterna is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Eterna Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eterna Therapeutics and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Eterna Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eterna Therapeutics has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Eterna Therapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and Eterna Therapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to generate 0.55 times more return on investment than Eterna Therapeutics. However, Syndax Pharmaceuticals is 1.8 times less risky than Eterna Therapeutics. It trades about -0.07 of its potential returns per unit of risk. Eterna Therapeutics is currently generating about -0.28 per unit of risk. If you would invest  1,806  in Syndax Pharmaceuticals on September 17, 2024 and sell it today you would lose (413.00) from holding Syndax Pharmaceuticals or give up 22.87% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Syndax Pharmaceuticals  vs.  Eterna Therapeutics

 Performance 
       Timeline  
Syndax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Eterna Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eterna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Syndax Pharmaceuticals and Eterna Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Syndax Pharmaceuticals and Eterna Therapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and Eterna Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Eterna Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eterna Therapeutics will offset losses from the drop in Eterna Therapeutics' long position.
The idea behind Syndax Pharmaceuticals and Eterna Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.